A Phase 3 interventional study of Guselkumab and Placebo in Crohn's Disease, sponsored by Janssen Research & Development, LLC. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.
Among the 13 studies testing guselkumab in Crohn Disease, this one is the 13th largest by enrollment, is the only one that started in 2023, is one of 8 in phase 3, and was the 6th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Austria, Belgium and 14 more countries
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 3
First in 2018; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 196 across the 13 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 5 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
63 studies in Crohn Disease by Johnson & Johnson: 16 open now, 23 under way, 10 of them phase 3. Of 38 finished, 16 (42%) have results posted.
Among the 63 studies in Crohn Disease by Johnson & Johnson, this one is the 37th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2023, is one of 23 in phase 3, and was the 46th registered.
Johnson & Johnson’s Crohn Disease studies by the year they started, since 1995.
5 of the studies testing guselkumab in Crohn Disease that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT07310095Xian-Janssen Pharmaceutical Ltd.A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | 2027-09-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies testing guselkumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Guselkumab Dose 1 subcutaneously (SC) followed by Dose 2 SC thereafter through Week 144. Participants with disease recurrence will receive guselkumab SC treatment.
Drug: Guselkumab
Participants will receive matching placebo injections subcutaneously. Participants with disease recurrence will receive guselkumab SC treatment.
Drug: Placebo
Guselkumab will be administered subcutaneously.
Also known as: CNTO1959
Placebo will be administered subcutaneously.
Percentage of Participants With Endoscopic Recurrence Prior to or at Week 48
Endoscopic recurrence was defined by modified Rutgeerts score greater than or equal to (\>=) i2a in neo-terminal ileum, anastomotic site, or its equivalent in gastrointestinal (GI) tract (e.g., colonic ulceration). The modified Rutgeerts score ranged from i0 to i4, where i0 (No lesions), i1 (less than \[\<\] 5 aphthous lesions), i2 (greater than \[\>\] 5 aphthous lesions with normal mucosa between lesions or skip areas of larger lesions or lesions confined to ileocolonic anastomosis \[\<1 centimeter (cm) in length\]), i2a (lesions confined to ileocolonic anastomosis \[including anastomotic stenosis\]), i2b (more than 5 aphthous ulcers or larger lesions, with normal mucosa in-between, in the neoterminal ileum \[with or without anastomotic lesions\]), i3 (diffuse aphthous ileitis with diffusely inflamed mucosa), i4 (large ulcers with diffuse mucosal inflammation or nodules or stenosis in neoterminal ileum). Higher score indicated worsening.
Time frame: Baseline (Day 1) up to Week 48
Percentage of Participants With Clinical Remission Without Disease Recurrence at Week 48
Clinical remission without disease recurrence at Week 48 was a composite endpoint defined by (1) Crohn's disease activity index (CDAI) \<150 at Week 48 \& (2) no endoscopic recurrence as defined by modified Rutgeerts score \< i2a by Week 48 \& (3) have not experienced disease recurrence. Disease recurrence was defined as (1) \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.
Time frame: At Week 48
Time to Disease Recurrence
Disease recurrence was defined by (1) a \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.
Time frame: Baseline (Day 1) up to Week 48
Percentage of Participants With No Abdominal Pain at Week 48
Abdominal pain free at Week 48 is defined as abdominal pain (AP) score = 0 at Week 48. The scoring was done on a 4-point scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain.
Time frame: At Week 48
Time To Recurrence of Symptoms
Time-to-recurrence of symptoms was defined as time to attaining an AP mean daily score \>1 (and also \>1 point higher than baseline) along with stool frequency (SF) mean daily score \>3 (and also \>3 higher per day than baseline) for 2 consecutive weeks through Week 48. AP score scaling was done on a 4-point score scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain. Stool frequency score was calculated from the total number of liquid or very soft stools in the previous 7 days.
Time frame: Baseline (Day 1) up to Week 48
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Number of participants with TEAEs and TESAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE/SAE occurring at or after the initial administration of study intervention through early termination of trial (up to Week 28) was considered to be treatment emergent.
Time frame: Baseline (Day 1) up to early termination of trial (up to Week 28)
Serum Guselkumab Concentrations Over Time
Serum guselkumab concentrations over time were reported. No summary analysis was done as study was terminated early and participant wise data were reported. This outcome measure was planned to be analyzed for "Guselkumab 200 mg + Guselkumab 100 mg" arm only.
Time frame: At Weeks 0, 8, 16
Percentage of Participants With Steroid Free Clinical Remission at Week 48
Steroid free clinical remission at Week 48 is defined as CDAI \<150 and no corticosteroids within 30 days. The CDAI was a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. The last 4 variables were scored over 7 days by the participant on a diary card. In general, CDAI score ranges from 0 to approximately 600; higher score indicated higher disease activities.
Time frame: At Week 48
A total of 4 participants who had recently undergone a surgical resection for Crohn's Disease (CD) were enrolled, randomized (1:1) and treated with study drug or placebo.
| Milestone | Guselkumab 200 mg + Guselkumab 100 mg | Placebo |
|---|---|---|
| Started | 2 | 2 |
| Treated at weeks 0, 8 and 16 | 1 | 2 |
| Treated at weeks 0, 8 | 1 | 0 |
| Completed | 0 | 0 |
| Not completed | 2 | 2 |
| Withdrew: Study terminated by sponsor | 2 | 2 |
Endoscopic recurrence was defined by modified Rutgeerts score greater than or equal to (\>=) i2a in neo-terminal ileum, anastomotic site, or its equivalent in gastrointestinal (GI) tract (e.g., colonic ulceration). The modified Rutgeerts score ranged from i0 to i4, where i0 (No lesions), i1 (less than \[\<\] 5 aphthous lesions), i2 (greater than \[\>\] 5 aphthous lesions with normal mucosa between lesions or skip areas of larger lesions or lesions confined to ileocolonic anastomosis \[\<1 centimeter (cm) in length\]), i2a (lesions confined to ileocolonic anastomosis \[including anastomotic stenosis\]), i2b (more than 5 aphthous ulcers or larger lesions, with normal mucosa in-between, in the neoterminal ileum \[with or without anastomotic lesions\]), i3 (diffuse aphthous ileitis with diffusely inflamed mucosa), i4 (large ulcers with diffuse mucosal inflammation or nodules or stenosis in neoterminal ileum). Higher score indicated worsening.
No measurements were reported for this outcome.
Clinical remission without disease recurrence at Week 48 was a composite endpoint defined by (1) Crohn's disease activity index (CDAI) \<150 at Week 48 \& (2) no endoscopic recurrence as defined by modified Rutgeerts score \< i2a by Week 48 \& (3) have not experienced disease recurrence. Disease recurrence was defined as (1) \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.
No measurements were reported for this outcome.
Disease recurrence was defined by (1) a \>=70 point increase from baseline in CDAI score at \>8 weeks after randomization \& CDAI score \>=200 and evidence of endoscopic recurrence (Rutgeerts score \<i2a) or (2) initiation of physician-prescribed corticosteroids or increase in steroid dose of \>5 milligrams per day (mg/day) for treatment of Crohn's disease (CD) and endoscopic recurrence or (3) new draining or reopening of an internal or external fistula or (4) new perianal abscess or (5) new intra-abdominal abscess more than 3 months post index surgery. If a patient tested positive for enteric pathogen, infection should be treated and then participant should be reassessed for whether they meet disease recurrence.
No measurements were reported for this outcome.
Abdominal pain free at Week 48 is defined as abdominal pain (AP) score = 0 at Week 48. The scoring was done on a 4-point scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain.
No measurements were reported for this outcome.
Time-to-recurrence of symptoms was defined as time to attaining an AP mean daily score \>1 (and also \>1 point higher than baseline) along with stool frequency (SF) mean daily score \>3 (and also \>3 higher per day than baseline) for 2 consecutive weeks through Week 48. AP score scaling was done on a 4-point score scale, ranged from 0 to 3, where 0 equals none, 1 equals mild, 2 equals moderate and 3 equals severe pain. Higher score indicated severe pain. Stool frequency score was calculated from the total number of liquid or very soft stools in the previous 7 days.
No measurements were reported for this outcome.
Number of participants with TEAEs and TESAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Any AE/SAE occurring at or after the initial administration of study intervention through early termination of trial (up to Week 28) was considered to be treatment emergent.
| Participants | Guselkumab 200 mg + Guselkumab 100 mg | Placebo |
|---|---|---|
| TEAEs | 1 | 1 |
| TESAEs | 1 | 1 |
Serum guselkumab concentrations over time were reported. No summary analysis was done as study was terminated early and participant wise data were reported. This outcome measure was planned to be analyzed for "Guselkumab 200 mg + Guselkumab 100 mg" arm only.
| micrograms/milliliters (ug/mL) | Guselkumab 200 mg + Guselkumab 100 mg |
|---|---|
| Participant 1 (Week 0) | 0 |
| Participant 1 (Week 8) | 1.68920 |
| Participant 1 (Week 16) | 0.70957 |
| Participant 2 (Week 0) | 0 |
| Participant 2 (Week 8) | 2.87917 |
Steroid free clinical remission at Week 48 is defined as CDAI \<150 and no corticosteroids within 30 days. The CDAI was a validated multi-item measure of severity of illness derived as a weighted sum of 8 different Crohn's disease-related variables. The CDAI score was assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. The last 4 variables were scored over 7 days by the participant on a diary card. In general, CDAI score ranges from 0 to approximately 600; higher score indicated higher disease activities.
No measurements were reported for this outcome.
Collected over Baseline (Day 1) up to 12 weeks after last study dose administration (up to Week 28). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Guselkumab 200 mg + Guselkumab 100 mg | 0/2 (0%) | 1/2 (50%) | 0/2 (0%) |
| Placebo | 0/2 (0%) | 1/2 (50%) | 0/2 (0%) |
| Event | Guselkumab 200 mg + Guselkumab 100 mg | Placebo |
|---|---|---|
| Campylobacter GastroenteritisInfections and infestations | 0/2 | 1/2 |
| NephrolithiasisRenal and urinary disorders | 1/2 | 0/2 |
Analysis was performed on all randomized participants. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, data were reported under a single arm.
| Age, Continuous(Years) | Overall Participants |
|---|---|
| Mean | 46.3 ± 6.75 |
| Age, Customized(Participants) | Overall Participants |
|---|---|
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 4 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |
| Sex: Female, Male(Participants) | Overall Participants |
|---|---|
| Female | 2 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 4 |
| Race (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Feb 2023 to primary completion in Sep 2023, 7 months.
Results were first posted in Oct 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →